Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) EV-to-EBIT : -141.79 (As of May. 13, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Sichuan Kelun-Biotech Biopharmaceutical Co EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sichuan Kelun-Biotech Biopharmaceutical Co's Enterprise Value is HK$38,757.7 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-273.3 Mil. Therefore, Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT for today is -141.79.

The historical rank and industry rank for Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT or its related term are showing as below:

HKSE:06990' s EV-to-EBIT Range Over the Past 10 Years
Min: -143.14 Med: -64.85 Max: -46.02
Current: -141.79

During the past 3 years, the highest EV-to-EBIT of Sichuan Kelun-Biotech Biopharmaceutical Co was -46.02. The lowest was -143.14. And the median was -64.85.

HKSE:06990's EV-to-EBIT is ranked worse than
100% of 436 companies
in the Biotechnology industry
Industry Median: 9.28 vs HKSE:06990: -141.79

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Sichuan Kelun-Biotech Biopharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$19,855.3 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-273.3 Mil. Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -1.38%.

Sichuan Kelun-Biotech Biopharmaceutical Co EV-to-EBIT Historical Data

The historical data trend for Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sichuan Kelun-Biotech Biopharmaceutical Co EV-to-EBIT Chart

Sichuan Kelun-Biotech Biopharmaceutical Co Annual Data

Trend

Dec21

Dec22

Dec23

EV-to-EBIT

-47.35

Sichuan Kelun-Biotech Biopharmaceutical Co Quarterly Data
	Sep21	Dec21	Jun22	Sep22	Dec22	Jun23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial			-	-	-	-	-47.35

Competitive Comparison of Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT

For the Biotechnology subindustry, Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT falls into.

Sichuan Kelun-Biotech Biopharmaceutical Co EV-to-EBIT Calculation

Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	38757.668	/	-273.339
	=	-141.79

Sichuan Kelun-Biotech Biopharmaceutical Co's current Enterprise Value is HK$38,757.7 Mil.
Sichuan Kelun-Biotech Biopharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-273.3 Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Sichuan Kelun-Biotech Biopharmaceutical Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-273.339	/	19855.2565
	=	-1.38 %

Sichuan Kelun-Biotech Biopharmaceutical Co's Enterprise Value for the quarter that ended in Dec. 2023 was HK$19,855.3 Mil.
Sichuan Kelun-Biotech Biopharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-273.3 Mil.

Sichuan Kelun-Biotech Biopharmaceutical Co EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Sichuan Kelun-Biotech Biopharmaceutical Co's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sichuan Kelun-Biotech Biopharmaceutical Co Ltd (HKSE:06990) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 666 Xinhua Avenue, Chengdu Cross-Strait Science and Technology Industry Development Park, Wenjiang, Sichuan, Chengdu, CHN

Website

http://www.kelun-biotech.com

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd is an innovative biopharmaceutical company committed to the R&D, manufacturing and commercialization of novel drugs to address medical needs in China and globally. It is one of the first movers in the development of antibody-drug conjugates (ADCs), with over a decade of accumulated experience in ADC development. The company takes a systematic, indication-oriented approach to target the world's prevalent or hard-to-treat cancers, and other diseases and conditions affecting a large and underserved population.

Sichuan Kelun-Biotech Biopharmaceutical Co (HKSE:06990) Headlines

No Headlines